Modifies provisions relating to gender transition procedures
HB1081 repeals and replaces Missouri’s existing section 191.1720 with a new law titled the “Missouri Save Adolescents from Experimentation (SAFE) Act.” The bill prohibits healthcare providers from knowingly performing gender transition surgery on any person under 18 and from prescribing or administering cross-sex hormones or puberty-blocking drugs to minors for the purpose of gender transition. It also defines key terms such as biological sex, gender transition, gender transition surgery, cross-sex hormones, and puberty-blocking drugs, and includes exceptions for certain individuals with medically verifiable disorders of sex development, treatment of complications, and emergency care.
The bill creates a delayed grandfathering provision for minors who were already receiving cross-sex hormones or puberty-blocking drugs before August 28, 2023, allowing that treatment to continue only until March 1, 2026. It also states that violations constitute unprofessional conduct and require revocation of the provider’s license by the appropriate licensing or disciplinary board. In addition, the bill creates a private right of action for affected individuals, with expanded damages, attorney’s fees, a long limitations period, and restrictions on confidentiality and waiver of claims.
HB1081 would significantly change Missouri law governing medical treatment for transgender minors by banning gender transition surgeries and most hormone- or puberty-blocking treatments for those under 18, while also creating professional discipline and civil liability for providers who violate the law. It would affect healthcare providers, licensing boards, minors seeking gender-affirming care, and potentially hospitals and clinics that offer such services. The bill also limits the application of existing medical malpractice provisions by excluding chapter 538 from actions brought under the new section and sets special rules for damages, venue, settlement approval, and confidentiality.
Based on the bill text and the absence of recorded committee debate or votes in the provided materials, the overall posture of the bill appears strongly restrictive toward gender-affirming care for minors and framed as a child-protection measure. The title and structure suggest support from sponsors and likely proponents who view the bill as preventing irreversible medical interventions on adolescents. No opposing testimony or recorded vote history is included here, so the available context does not show a formal legislative split, but the subject matter is typically highly contentious.
The main points of contention are likely the bill’s ban on gender transition surgery and hormone/puberty-blocking treatment for minors, the scope of the exceptions, and the creation of severe penalties for providers, including license revocation and civil liability. Critics would likely focus on the impact on transgender youth, medical decision-making, and access to care, while supporters would emphasize protecting minors from irreversible treatment. The private right of action, enhanced damages, and long statute of limitations are also notable flashpoints because they increase legal exposure for healthcare providers and may deter treatment even in borderline or exception cases.